One infusion of natalizumab (300 mg or 3 mg/kg) probably leads to lower failure to induce remission at 2 weeks compared with placebo (moderate certainty).
One infusion of natalizumab (300 mg or 3 mg/kg) leads to lower failure to induce remission at 4 weeks compared with placebo (high certainty).
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in failure to induce clinical response at 2 weeks compared with placebo (moderate certainty).
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in adverse events up to week 12 compared with placebo (moderate certainty).
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in withdrawal due to adverse events up to week 12 compared with placebo (low certainty).
One infusion of natalizumab (300 mg or 3 mg/kg) showed no clear difference in serious adverse events up to week 12 compared with placebo (low certainty).